Lonza Group Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Lonza Group Bundle
Unlock a strategic Business Model Canvas: value propositions, partners, revenue streams
Unlock Lonza Group’s strategic blueprint with our Business Model Canvas—detailing value propositions, key partners, revenue streams and scaling levers. Ideal for investors, consultants and founders seeking actionable insight. Download the full Word/Excel canvas to apply it now.
Partnerships
Pharma and biotech sponsors
Lonza partners with large pharma and emerging biotech to co-develop and manufacture drug substances and products, covering discovery support, clinical supply and commercial production; in 2024 it served over 1,000 pharma/biotech customers worldwide. Master service agreements provide frameworks for multi-asset collaboration, while joint governance models enable rapid decisions and shared risk across portfolios.
Technology and platform providers
Alliances with platform innovators in mRNA, viral vectors, cell lines and analytics expand Lonza’s service scope and enabled its long-term manufacturing collaboration with Moderna; by 2024 Lonza employed roughly 15,000 staff supporting expanded biologics capacity. Access to cutting-edge tools accelerates development and improves yields, while co-validation embeds technologies into GMP workflows and joint roadmaps keep capabilities ahead of emerging modalities.
Equipment and single-use vendors
Strategic ties with bioreactor, filtration and fill-finish suppliers secure reliable, scalable hardware and help Lonza support high-demand biologics manufacturing; single-use systems cut cleaning/turnaround time by about 90%, accelerating batch cadence. Early vendor involvement de-risks tech transfer and scale-up, improving first-batch yields and time-to-market. Standardization across sites reduces downtime and variability, while preferred pricing and priority support protect timelines and capacity commitments.
Raw material and critical reagent suppliers
Lonza secures diversified suppliers for media, resins, lipids and excipients to ensure campaign continuity, backed by formal quality agreements and regular supplier audits that uphold regulatory compliance.
Safety stocks and dual sourcing policies mitigate shortages while collaborative demand planning aligns supplier lead times with manufacturing campaign schedules.
- Diversified sourcing
- Quality agreements & audits
- Safety stock & dual sourcing
- Collaborative planning
Regulators and academic institutions
Proactive engagement with regulatory bodies shapes compliant processes and accelerates approvals through early scientific advice for CMC and submission strategies, while scientific partnerships with universities sustain innovation and talent pipelines. Participation in consortia informs best practices and harmonizes standards across biologics and cell therapy manufacturing.
- Regulatory engagement: early scientific advice to streamline CMC
- Academic ties: research collaboration and talent flow
- Consortia: shared best practices and standards
CDMO scales mRNA, viral vector and analytics services to over 1,000 pharma customers
Lonza serves over 1,000 pharma/biotech customers via MSAs and joint governance for multi-asset CDMO projects.
Alliances in mRNA, viral vectors and analytics plus co-validation support scale; workforce ~15,000 (2024).
Diversified suppliers, safety stock/dual sourcing and single-use systems (≈90% cleaning/turnaround reduction) secure campaigns.
| Metric | Value (2024) |
|---|---|
| Customers | >1,000 |
| Employees | ~15,000 |
| Cleaning time reduction | ≈90% |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas for Lonza Group detailing its nine blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—aligned with the company’s real-world CDMO and life-sciences operations. Ideal for presentations and investor discussions, it includes competitive advantages and linked SWOT insights to support strategic decisions and validation.
Customizable Excel Spreadsheet
High-level view of Lonza's biopharma-focused business model with editable cells, relieving pain from complex partner ecosystems and regulatory fragmentation by aligning R&D, manufacturing and commercial teams quickly. Perfect for boardrooms, strategy sessions and rapid competitor comparisons.
Activities
Process and analytical development
Design and optimization of upstream, downstream and analytical methods are core to Lonza’s service offering, with process development driven by modular platform solutions. According to Lonza’s 2024 annual report, robust DoE and comparability studies embed quality by design across projects. Platform approaches shorten timelines across modalities and standardized tech packages are prepared for seamless GMP transfer.
GMP manufacturing drug substance
GMP manufacturing of drug substance at Lonza spans clinical and commercial-scale biologics, small molecules and advanced therapies (ATMPs), with batch execution under validated SOPs and ALCOA+ data-integrity standards. Capacity planning balances multi-tenant operations across ~20 global sites serving 100+ clients. Continuous-improvement programs delivered ~5% yield gains and ~8% throughput increases in 2024.
Drug product and fill-finish
Sterile filling, lyophilization and oral solid dose capabilities close Lonza’s end-to-end value chain, supporting both biologics and small-molecule launches in 2024. Container-closure systems, automated visual inspection and packaging processes protect product quality and regulatory compliance. Continuous environmental monitoring underpins aseptic assurance while cold-chain logistics and serialization enable secure global distribution.
Quality, regulatory, and validation
Quality Management Systems, QC testing and method validation underpin regulatory compliance and batch release; CMC authoring and dossier support enable global filings while qualification of facilities, utilities and equipment is maintained across over 30 manufacturing sites (2024). Continuous audit readiness and CAPA execution drive sustained compliance and risk reduction.
- QMS: standardized controls across >30 sites (2024)
- QC testing: batch release and stability programs
- Method validation: regulatory-grade assays
- Audit/CAPA: continuous improvement loop
Tech transfer and scale-up
Platform-led process development shortens timelines; 5% yield & 8% throughput gains
Lonza delivers platform-driven process development and DoE-enabled comparability, shortening timelines across modalities. GMP manufacturing spans clinical-to-commercial biologics, small molecules and ATMPs across ~20 sites serving 100+ clients. QMS and QC cover >30 sites with 5% yield and 8% throughput gains in 2024.
| Metric | 2024 |
|---|---|
| Sites (GMP/QMS) | ~20 / >30 |
| Clients served | 100+ |
| Yield gain | ~5% |
| Throughput gain | ~8% |
What You See Is What You Get
Business Model Canvas
The document you're previewing is the actual Lonza Group Business Model Canvas you will receive after purchase. It's not a mockup—this preview is taken directly from the final editable file. After buying, you'll download the same complete, professionally formatted canvas ready for immediate use.
Resources
Global GMP sites and suites
Lonza’s global GMP sites across North America, Europe and Asia-Pacific deliver multi-modal capacity and redundancy, with dedicated suites for biologics, small molecules and advanced therapies ensuring fit-for-purpose environments; modular, single-use setups enable rapid changeover and scale, while robust utilities and infrastructure protect uptime and supply continuity.
Skilled scientists and engineers
Cross-functional experts in process, analytics, QA and regulatory at Lonza drive performance, supported by a workforce of roughly 15,000 employees (2023) delivering integrated CDMO services. Deep experience across biologic and small‑molecule modalities speeds troubleshooting and reduces time‑to‑clinic. Program managers orchestrate complex timelines across multicenter projects. Ongoing training programs sustain best‑in‑class capabilities.
Proprietary platforms and know-how
Lonza’s proprietary platforms, optimized cell lines, and tailored formulations accelerate candidate progression by shortening development pathways. Codified SOPs and playbooks reduce operational risk and variability across manufacturing sites. Integrated data models and historical benchmarks guide go/no-go decisions and scale-up strategies. Trade secrets and tacit knowledge enhance reproducibility and technical transfer success.
Digital and data infrastructure
As of 2024, Lonza's digital and data infrastructure—eBR, LIMS, QMS and consolidated data lakes—supports regulatory compliance and analytics; real-time monitoring and CPV enhance process control, electronic traceability accelerates investigations, and secure integrations provide sponsor visibility.
- eBR/LIMS/QMS: compliance backbone
- Data lakes: cross-program insights
- Real-time CPV: tighter control
- Traceability: faster investigations
- Secure APIs: sponsor transparency
Supplier and partner ecosystem
Preferred networks secure priority access to critical materials and technology, reducing supply disruptions for Lonza and enabling sustained CDMO output. Strategic alignment with key suppliers stabilizes costs and lead times, supporting predictable margins. Joint forecasting with partners improves availability and inventory turns, while collaboration accelerates adoption of new biologics manufacturing innovations.
- priority access
- cost & lead-time stability
- improved availability
- faster innovation adoption
Global GMP network, modular single-use suites and rapid scale-up with ~15,000 experts
Lonza's global GMP network and modular single-use suites provide multi-modal, redundant capacity and rapid scale-up. A ~15,000-strong workforce (2023) of cross-functional experts and program managers sustains integrated CDMO delivery and regulatory compliance. Proprietary platforms, SOPs and 2024 digital systems (eBR/LIMS/QMS, data lakes) shorten development timelines and improve traceability.
| Metric | Value |
|---|---|
| Employees (2023) | ~15,000 |
| Infrastructure | Global GMP sites (NA/EU/APAC) |
Value Propositions
End-to-end CDMO solutions
End-to-end CDMO solutions consolidate development-to-commercial supply, cutting handoffs and change orders; single-point accountability reduces program risk while coordinated timelines accelerate time-to-clinic and market entry. Sponsors gain simplicity and predictability as the global CDMO market—valued at about $160 billion in 2023—continues growing at roughly an 11% CAGR into 2030.
Speed and scalability
Platform methods and ready capacity shorten cycle times, with Lonza's flexible scale supporting Phase I through commercial production and serving thousands of programs worldwide. Rapid scale-up frameworks cut typical tech-transfer delays, enabling expedited options to meet urgent milestones. As of 2024 Lonza operates globally and employs about 16,000 staff, underpinning fast deployment and scale.
Quality and regulatory excellence
Lonza’s strong QMS and 2024 inspection track record de-risk submissions, backed by CHF 5.3bn in 2024 revenue demonstrating scale; comprehensive CMC support accelerates global approvals, while strict data integrity and transparency build regulator and partner trust; robust validation frameworks ensure consistent product quality and batch-to-batch reproducibility.
Modality breadth and expertise
Lonza’s capabilities span biologics, small molecules and advanced therapies, delivering tailored development-to-commercialization solutions; in 2024 Lonza reported CHF 6.3 billion in revenue, underscoring scale. Deep technical know-how improves yields and process robustness, while specialized suites and containment enable safe handling of complex modalities and high-risk assets.
- Capabilities: biologics, small molecules, cell & gene
- Scale: 2024 revenue CHF 6.3bn
- Strength: yield & robustness improvement
- Safety: specialized containment suites
- Customization: asset-tailored solutions
Reliability and supply resilience
Lonza's multi-site footprint across Europe, North America and Asia plus dual sourcing protects continuity; mature S&OP stabilizes campaigns and reduces variability. Robust risk-management limits disruptions and transparent, real-time communication in 2024 keeps sponsors aligned on timelines and inventory positions.
- Multi-site, dual-sourcing
- Mature S&OP
- Risk management
- Transparent sponsor communication
Integrated CDMO platform speeds time-to-clinic; CHF 6.3bn revenue
Lonza offers integrated end-to-end CDMO services that reduce handoffs, lower program risk and speed time-to-clinic in a CDMO market valued at about $160bn in 2023 with ~11% CAGR to 2030. Platform processes and global capacity enable rapid scale from Phase I to commercial; 2024 revenue CHF 6.3bn and ~16,000 employees underpin delivery. Multi-site, dual-sourcing and strong QMS de-risk supply and regulatory pathways.
| Metric | Value |
|---|---|
| 2024 revenue | CHF 6.3bn |
| Employees | ~16,000 |
| CDMO market (2023) | $160bn |
| CAGR to 2030 | ~11% |
Customer Relationships
Dedicated program teams
Dedicated program teams provide single points of contact that coordinate cross‑functional work and ensure project continuity; in 2024 Lonza (SIX: LONN) applies this across its global pharma operations. Regular governance meetings track progress and risks. Clear escalation paths resolve issues rapidly while collaborative tools maintain alignment.
Long-term strategic agreements
Long-term strategic agreements at Lonza use framework MSAs to streamline new project starts, reducing setup friction and accelerating timelines; in 2024 the global CDMO market was estimated at about $83.5bn, underscoring demand for predictable capacity. Volume commitments secure manufacturing slots and de-risk investments, while multi-asset roadmaps deepen partnership value across modalities. Clear performance KPIs (yield, on-time delivery, cost per batch) drive continuous improvement and contract renewals.
Technical collaboration and co-development
Joint development plans at Lonza align CQA and CPP targets to de‑risk scale‑up, leveraging 2024 group revenue of CHF 5.2bn to fund capabilities; shared data rooms enable rapid decisions, shortening milestone approvals to days; targeted co‑investment deals accelerate capability fit and can cut integration timelines by ~40%; embedded scientific advisory panels provide continual problem‑solving across projects.
Transparency and audit readiness
Open access to batch records and deviations builds client confidence by enabling immediate verification of manufacturing history and change controls.
Sponsor audits are supported proactively with dedicated audit teams and streamlined documentation workflows to shorten response times and improve findings closure rates.
CAPA status is communicated frequently through automated notifications, while metrics dashboards provide real-time visibility into deviations, investigations, and corrective actions.
- transparent batch access
- proactive sponsor audit support
- frequent CAPA updates
- real-time metrics dashboards
Lifecycle and post-launch support
Lifecycle and post-launch support at Lonza centers on ongoing PPQ, CPV, and change control to sustain supply, with 2024 operations supporting global commercial supply across multiple sites and contributing to reported 2024 revenue of CHF 6.1bn.
Yield optimization and cost-down initiatives delivered measurable savings in 2024, enabling line extensions and reformulations while obsolescence planning reduced supply-risk exposure.
- PPQ/CPV: continuous monitoring
- Yield gains: ongoing cost-down programs
- Line extensions: reformulation support
- Obsolescence: proactive risk plans
Program teams shorten approvals; CHF 6.1bn, USD 83.5bn CDMO market
Dedicated program teams provide single points of contact and regular governance, shortening approvals and escalations across global pharma ops; Lonza reported CHF 6.1bn revenue in 2024. Framework MSAs and volume commitments secure capacity in a ~USD 83.5bn CDMO market (2024), driving renewals via KPI‑led performance. Lifecycle PPQ/CPV, CAPA dashboards and proactive audit support sustain supply and reduce risk.
| Metric | 2024 value |
|---|---|
| Group revenue | CHF 6.1bn |
| Global CDMO market | USD 83.5bn |
| Integration timeline cut (co‑invest) | ~40% |
Channels
Direct sales and key accounts
Business development and KAM teams engage target sponsors, leveraging Lonza’s relationship-led selling to align solutions with sponsor pipelines; account plans map asset needs to capacity while executive sponsorship secures cross‑functional commitment. Lonza served over 1,000 customers and employed ~16,000 people in 2024.
Scientific conferences and industry forums
Presentations at scientific conferences (eg CPhI, which attracts ~45,000 attendees) showcase Lonza case studies and technical capabilities, driving brand reach; booths and targeted meetings historically convert 5–10% of interactions into qualified leads, feeding the sales funnel. Thought leadership sessions and white papers bolster credibility with KOLs and buyers, while networking at forums accelerates partnerships and BD opportunities that supported Lonza’s commercial growth in 2024.
Digital presence and portals
Lonza’s website showcases services, capacity and case stories, driving credibility and lead capture while aligning with 2024 data showing 86% of B2B buyers start research online. Secure client portals deliver real-time project visibility and document exchange for GMP programs. Regular webinars educate prospects on platforms and process capabilities, while targeted digital campaigns reach decision-makers through account-based channels and programmatic ads.
Strategic alliances and referrals
Allied consultants and VCs routinely recommend Lonza services to portfolio companies, accelerating deal flow; platform partners co-market integrated CDMO+tech solutions; joint proposals with partners expand geographic and therapeutic reach; positive sponsor references from existing clients (Lonza serves 1,000+ customers) materially boost adoption.
- referrals: VC/consultant-driven pipeline
- co-marketing: platform partner campaigns
- joint-bids: expanded RFP success
- references: 1,000+ customers
RFPs and procurement platforms
Participation in RFPs and procurement platforms secures larger, multi-year CDMO mandates and upsized contracts. Standardized, pre-approved responses shorten evaluation cycles and speed award decisions. Lonza’s focus on quality and rapid delivery differentiates bids and eases onboarding under framework agreements; as of 2024 Lonza employed about 16,000 people globally.
- Win larger mandates via formal RFPs
- Standardized responses reduce evaluation time
- Quality and speed = competitive edge
- Frameworks enable rapid onboarding
Relationship-led selling and events convert pipelines into leads at 5–10%
Business development and KAMs use relationship-led selling and account plans to convert pipelines; Lonza served 1,000+ customers and employed ~16,000 people in 2024. Conferences (eg CPhI ~45,000 attendees) and thought leadership convert 5–10% of interactions to leads. Digital channels capture leads (86% B2B research online); RFPs and partner referrals expand multi-year mandates.
| Metric | 2024 |
|---|---|
| Customers | 1,000+ |
| Employees | ~16,000 |
| CPhI attendees | ~45,000 |
| B2B online research | 86% |
Customer Segments
Large pharmaceutical companies
Large pharmaceutical companies increasingly outsource to add flexibility and cut fixed costs, driving demand for late-stage and commercial supply partners. They require high compliance and reliability—GMP, GDP and continuous quality oversight—and favor multi-asset, integrated CDMO relationships. The global pharma outsourcing market was valued at USD 64.9bn in 2021 and is projected to reach USD 136.9bn by 2028, underscoring scale and growth.
Venture-backed biotechs
Early-stage, venture-backed biotechs prioritize speed and development guidance, with milestone-driven budgets and tight timelines (typical CMC and IND-ready work 12–36 months). They require support from preclinical through Phase II and value high-touch program management and integrated CDMO partnerships. Many aim to reach Phase II on Series A/B funding rounds, often sized to cover key milestones.
Advanced therapy developers
Companies developing cell, gene and mRNA therapies require specialized suites and technical know-how to produce small-batch, high-value products under GMP; CAR-T therapies can cost roughly $373,000–$475,000 per treatment, underscoring value density. Rapid iteration across process development and scale-down models is essential to de-risk clinical timelines. Ongoing regulatory support for IND/BLA filings and comparability studies is critical to accelerate approvals.
Vaccine and biologics producers
Vaccine and biologics producers—focused on monoclonal antibodies, vaccines and recombinant proteins—require scalable bioprocessing and flexible capacity to meet seasonal or surge demand; cold-chain logistics and aseptic fill-finish are critical for product integrity and regulatory approval.
Global filings push strong CMC capabilities, driving partnerships with CDMO providers that offer scalable stainless-steel and single-use systems plus end-to-end cold-chain solutions.
- Scalable mammalian and microbial bioprocessing
- Flexible surge capacity and seasonal readiness
- Cold-chain + aseptic fill-finish
- Robust CMC for global regulatory filings
Consumer health and nutrition brands
Consumer health and nutrition brands demand pharma-grade ingredients, dosage-form expertise and supply reliability to support launches; the global dietary supplements market was estimated at about USD 178 billion in 2024, driving emphasis on compliance and traceability for market access. Differentiated delivery technologies such as encapsulation and sustained-release add measurable product premium and shelf differentiation.
CDMO demand surges: GMP-compliant multi-asset supply, rapid CMC, traceable ingredients
Large pharma seeks reliable, compliant multi-asset CDMO partnerships for late-stage and commercial supply. Venture-backed biotechs need fast, milestone-driven development (CMC/IND 12–36 months) and high-touch program management. Cell/gene/mRNA developers require specialized GMP suites and comparability/regulatory support; consumer health demands pharma-grade ingredients and traceability—global dietary supplements USD 178bn in 2024.
| Segment | Key needs | Market size |
|---|---|---|
| Large pharma | GMP/GDP, integrated CDMO | Outsourcing USD 64.9bn (2021); USD 136.9bn (2028) |
| Consumer health | Pharma-grade ingredients, traceability | Dietary supplements USD 178bn (2024) |
Cost Structure
CapEx for facilities and equipment
CapEx for GMP suites, bioreactors, isolators and QC labs is material for Lonza, with 2024 capital expenditures of CHF 742 million supporting expansions and modernization to stay competitive. Regular upgrades and new facility builds drive ongoing spend. Depreciation represents a major fixed cost on the income statement. Validation and qualification add significant upfront expense before revenue generation.
Skilled labor and training
Personnel costs for scientists, operators, QA and regulatory drive a large share of Lonza’s cost base; the company employed about 17,000 people in 2024, concentrating labor expense in manufacturing and technical roles. Continuous training and qualification programs maintain GMP compliance and recurring certification costs. Shift premiums for 24/7 operations typically uplift wage bills by roughly 10–20%, while ongoing recruitment and retention programs add sustained HR and SG&A pressure.
Materials and consumables
Media, resins, single-use systems and excipients drive Lonza’s variable costs; the single-use systems market exceeded $10bn in 2024. Price volatility is managed via hedging strategies and multi-year supply contracts. Scrap and yield losses are tightly controlled (targets <5%), while inventory holding is optimized to balance service risk and cash.
Quality, compliance, and audits
Quality, compliance, and audits drive recurring costs at Lonza: QC testing, method validation, and documentation create ongoing lab and personnel expenses; regulatory interactions and inspections require dedicated teams and external consultancy; CAPA and change-control processes consume operational effort; digital compliance tools need software licenses and maintenance. In 2024 Lonza operated with approximately 17,000 employees, many supporting these functions.
- QC testing: recurring lab costs
- Method validation: protocol & personnel
- Regulatory inspections: dedicated resources
- CAPA/change control: continuous effort
- Digital tools: license & maintenance fees
Utilities, logistics, and insurance
Clean utilities, HVAC and energy are major cost drivers for Lonza, representing a significant share of manufacturing OPEX; Lonza reported CHF 6.1 billion revenue in 2024 while investing heavily in utility resilience to support bioprocessing demand.
- Utilities & HVAC: >20% of site OPEX
- Cold-chain logistics: premium +15–30% vs standard shipping
- Security & insurance: limits operational loss exposure
- Waste handling: ensures regulatory compliance
CapEx and labour strain margins: CHF 742m, ~17,000 staff, utilities > 20%
Major fixed costs: CHF 742m CapEx in 2024, depreciation from GMP suites and labs; personnel ~17,000 employees drive labour and training expense. Variable costs: media, single‑use systems (single‑use market >$10bn in 2024), resins and yield losses. Quality, compliance and utilities (>20% site OPEX) add recurring lab, audit and energy spend, plus cold‑chain premiums of 15–30%.
| Metric | 2024 |
|---|---|
| Revenue | CHF 6.1bn |
| CapEx | CHF 742m |
| Employees | ~17,000 |
| Utilities | >20% site OPEX |
Revenue Streams
Development and R&D services
Fees for process, analytical and formulation development generate early revenue for Lonza, with development services feeding a portion of the Group’s CHF 6.2 billion 2024 sales. Engagements use time-and-materials or milestone pricing, capturing high-margin expertise in biotech process optimization. Repeat development work often converts into longer-term manufacturing contracts, strengthening lifetime customer value.
GMP manufacturing and supply
Recurring revenues from clinical and commercial GMP batches dominate Lonza’s CDMO income; in 2024 Lonza reported CHF 6.3bn in revenue with GMP services accounting for the majority of CDMO sales. Pricing reflects scale, complexity and yield; multi-year supply agreements add predictability, and volume-based rebates/tiers are commonly applied.
Tech transfer and setup fees
One-time tech transfer and setup fees cover onboarding, process validation, and equipment changeover, ensuring Lonza recovers initial capital and operational expenses. Structured milestone gates tie payments to defined transfer stages, aligning client commitment with delivery. This gating reduces scope creep and materially improves revenue recognition and forecast accuracy across CDMO projects.
Milestones and success payments
Milestones and success payments align incentives by tying contingent payments to regulatory approvals or commercial launches, rewarding speed and quality; Lonza reported CHF 6.0bn revenue in 2024 with milestone-related receipts exceeding CHF 200m, highlighting material upside. Risk-sharing via these payments strengthens partnerships and supplements base fees at program inflection points.
- Contingent alignment
- Rewards speed & quality
- Risk-sharing bolsters ties
- Supplements base fees
Licensing and premium services
Licensing of Lonza’s proprietary platforms and delivery technologies generates recurring license fees and milestone payments, while expedited manufacturing slots and dedicated suites command premium pricing for faster time-to-market. Data analytics and CPV services enhance product differentiation and margin through actionable insights. Post-launch optimization and tech-transfer support create incremental, service-based revenue streams.
- License fees from platform access
- Premiums for expedited slots/suites
- Revenue from data analytics and CPV services
- Incremental income via post-launch optimization
Development fees and milestones fuel early cash; GMP batches drove CHF 6.3bn in 2024
Development fees and T&M/milestone pricing drive early revenue and often convert into long-term manufacturing contracts. Recurring clinical/commercial GMP batches dominate CDMO income; Lonza reported CHF 6.3bn revenue in 2024. Milestone-related receipts exceeded CHF 200m, while licensing, expedited suites and data services add premium, recurring streams.
| Stream | 2024 metric |
|---|---|
| Total revenue | CHF 6.3bn |
| Milestones | > CHF 200m |
| GMP/recurring | Majority of CDMO sales |